Ephrin type-A receptor 2 regulates sensitivity to paclitaxel in nasopharyngeal carcinoma via the phosphoinositide 3-kinase/Akt signalling pathway. This evidence concerns the gene AKT1 and nasopharyngeal carcinoma.